Luzerner Kantonsspital
Lucerne, 6000, Switzerland
Location status: Recruiting
NCT Number: NCT06062693
Primary objective of this study is to explore the impact of a 3-week upper limb hand function training in patients with PD, MS or stroke. The benefits on hand function of this training program will be evaluated. The hypothesize is that the 3-week upper limb hand function training improves finger dexterity.
Interested in participating?
Request Info18 year–99 year
All sexes
Interventional
Not applicable
Lucerne, 6000, Switzerland
Location status: Recruiting
Patients with Parkinson's disease (PD), multiple sclerosis (MS) or stroke often suffer from significantly decreased coordination and have difficulties with precise hand/finger movements during the performance of both basic activities of daily living (ADL), such as dressing, grooming as well as higher ADL, such as cooking, shopping and regular medication intake. The investigators explore the effects of a new, interactive, sensor-home-based upper limb hand training on upper limb related ADL in patients with PD, MS or stroke.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
or
Exclusion criteria
The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
Time frame: 3 weeks
Nine Hole Peg test (9-HPT): The 9-HPT is a standardized, well established, and reliable measure of hand dexterity in patients with PD, MS, or stroke. seconds will be measured.
Time frame: 3 weeks
Coin rotation task (CRT): The CRT measures fine coordinated finger movements and is a suitable and valid dexterity test in patients with PD, MS, or stroke. The seconds for 20 halfturns will be measured.
Time frame: 3 weeks
The handheld JAMAR dynamometer measures the grip strength. kg will be measured.
Time frame: baseline
Montreal Cognitive Assessment (MOCA): Cognitive screening tool with a scale from 0 - 30 points. A higher score means a better outcome.
Time frame: 3 weeks
Trail Making Tests (TMT) parts A & B. Results for both TMT A and B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.
Time frame: 3 weeks
Stroop-test: Results are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.
Time frame: 3 weeks
Patients with PD: Dexterity Questionnaire 24 (DextQ-24): This questionnaire is a standardized patient self-rated outcome measure (PROM) for evaluating dexterity related ADL in PD. score range 24-96, higher scores mean more dexterity problems.
Time frame: 3 weeks
Patients with MS: The Arm Function in Multiple Sclerosis Questionnaire (AMSQ): This questionnaire is a standardized patient self-rated outcome measure (PROM) for evaluating arm and hand function in patients with MS. Containing 31 items with a range of 1 - 100 points. Higher scores indicate more limitations in hand and arm function.
Time frame: 3 weeks
Patients with stroke: Upper limb limos: Mesures arm and hand function in ADL.
Contact information is provided by the study sponsor or research team.
Luzerner Kantonsspital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04876339
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Pavia, Italy
View Trial DetailsNCT05819008
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Umeå, Sweden
View Trial DetailsNCT03969927
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Kansas City, Kansas, United States
View Trial DetailsNCT05493514
Acquired Brain Injury, Autoimmune Diseases
Milan, Italy
View Trial Details